Cover image for Natural compounds in cancer therapy
Natural compounds in cancer therapy
Boik, John.
Personal Author:
Publication Information:
Princeton, Minn. : Oregon Medical Press, [2001]

Physical Description:
xiii, 521 pages : illustrations ; 28 cm
Format :


Call Number
Material Type
Home Location
Item Holds
RC271.A62 B655 2001 Adult Non-Fiction Central Closed Stacks-Oversize

On Order



Natural Compounds in Cancer Therapy is a classic reference work for patients and medical professionals interested in use of nontoxic botanical compounds in the treatment of cancer. It offers a snapshot of the field circa 2001, and its insights are still pertinent today. Natural Compounds in Cancer Therapy is among the first books to discuss the use of natural products against cancer from a systems biology perspective.

Reviews 1

Choice Review

This authoritative and thorough review of the use of natural products to prevent, slow, or reverse cancer is one of the best in the field of herbal medicine. Boik, with degrees in acupuncture and Oriental medicine, provides a much-needed compendium of in vitro and animal studies and human trials that even-handedly delineates the current state of knowledge about natural therapies used in cancer treatment. Compared with his first book, Cancer & Natural Medicine: A Textbook of Basic Science and Clinical Research (1995), which discussed hundreds of substances, this work focuses on 38 natural compounds with the most promise in treating cancer. Parts 1 and 2 review the many events in cancer progression at the levels of the cell and the organism. Part 3 discusses in detail the 38 individual compounds, evidence for their efficacy, and clinical outcomes. The writing style is comparable to that of Scientific American Medicine. Although there is a wealth of technical information, the use of numerous charts, cross-referencing, and primers on cancer development and immunology makes the book user-friendly. This valuable resource is highly recommended for physicians and their patients, researchers, pharmacists, nurses, educators, and laypersons seeking reliable information about complementary cancer therapies. General readers; graduate students through professionals. P. Wermager University of Hawaii at Manoa

Table of Contents

Contentsp. iii
Forewordp. vii
Prefacep. ix
1 Background for Parts I and IIp. 1
Development of Cancer and Characteristics of Cancer Cellsp. 1
Seven Strategies for Cancer Inhibitionp. 2
Using Natural Compounds in Combinationp. 4
Introduction to the Compoundsp. 5
Practical Considerations on Effective Concentrations and Scaling of Dosesp. 8
Referencesp. 10
Part I Cancer at the Cellular Level
2 Mutations, Gene Expression, and Proliferationp. 13
DNA, RNA, and Gene Expressionp. 13
Cell Proliferationp. 15
Mutations During Carcinogenesis and Progressionp. 17
How Natural Compounds and Chemotherapy Drugs Inhibit Proliferationp. 23
Cytosine Methylation and DNA: A Note on Cancer Preventionp. 25
Conclusionp. 26
Referencesp. 27
3 Results of Therapy at the Cellular Levelp. 29
Cell Differentiationp. 29
Failure to Enter the Cell Cyclep. 31
Apoptosis and Necrosisp. 31
Conclusionp. 33
Referencesp. 34
4 Growth Factors and Signal Transductionp. 37
Proliferation and Apoptosis in Normal Cells Versus Cancer Cellsp. 37
Growth Factorsp. 38
Signal Transductionp. 39
Conclusionp. 47
Referencesp. 47
5 Transcription Factors and Redox Signalingp. 51
Introduction to Redox Reactionsp. 51
Transcription Factorsp. 54
Mechanisms of Redox Modulationp. 60
Conclusionp. 61
Referencesp. 62
6 Cell-To-Cell Communicationp. 67
Cell Adhesion Moleculesp. 67
Gap Junctionsp. 71
Conclusionp. 72
Referencesp. 72
Part II Cancer at the Level of the Organism
7 Overview of Angiogenesisp. 79
Mechanics of Angiogenesisp. 79
Angiogenic Factors and Angiogenesis Inhibitionp. 80
Similarity of Angiogenesis in Wound Healing and Cancerp. 81
Wound Healing and Angiogenic Factorsp. 81
Conclusionp. 88
Referencesp. 88
8 Natural Inhibitors of Angiogenesisp. 91
Inhibition of Angiogenic Factorsp. 91
Additional Natural Compounds That may Inhibit Angiogenesisp. 97
Conclusionp. 98
Referencesp. 98
9 Invasionp. 105
Connective Tissue and the Extracellular Matrixp. 105
The ECM and Cancerp. 105
Glycosidases, Proteases, and Cancerp. 107
Enzyme Inhibitorsp. 107
Adhesion Proteins and Cancer Cell Migrationp. 110
Conclusionp. 111
Referencesp. 111
10 Metastasisp. 113
Steps of Metastasisp. 113
Cell Detachment and Movement into a Vesselp. 113
Migration Through the Circulationp. 114
Cell Arrest at a New Locationp. 114
Movement Out of the Vesselp. 116
Induction of Angiogenesisp. 116
Conclusionp. 116
Referencesp. 116
11 The Immune Systemp. 119
Innate and Adaptive Immunityp. 119
Antigens and Antibodiesp. 121
MHC Moleculep. 122
Role of Cytokines in Immunityp. 123
Role of Immune Cells in Cancerp. 123
Role of the Immune System in Cancer Preventionp. 124
Immune System in Cancer Treatmentp. 125
Conclusionp. 128
Referencesp. 128
12 Natural Compounds that Affect the Immune Systemp. 131
Natural Compounds That Stimulate and/or Support the Immune Systemp. 131
Clinical Studies with Chinese Herbal Formulasp. 135
Natural Compounds That Suppress the Immune Systemp. 137
Conclusionp. 139
Referencesp. 140
Part III Clinical Considerations
13 Background for Part IIIp. 147
Synergismp. 147
Estimating Effective and Safe Dosesp. 153
Available Formulationsp. 156
Combination Designp. 157
Conclusionp. 159
Referencesp. 160
14 Trace Metalsp. 163
Seleniump. 163
Ironp. 168
Copperp. 171
Conclusionp. 172
Referencesp. 173
15 Vitamin C and Antioxidantsp. 179
Vitamin Cp. 180
Antioxidantsp. 188
Conclusionp. 196
Referencesp. 196
16 Polysaccharidesp. 203
Introduction to Polysaccharidesp. 203
Individual Compoundsp. 203
Estimated Therapeutic and LOAEL Doses of Polysaccharidesp. 208
Using Combinations of Polysaccharidesp. 209
Conclusionp. 209
Referencesp. 210
17 Lipidsp. 215
Types of Dietary Fat and Their Sourcesp. 215
Stimulation of Cancer Progression by Saturated and Omega-6 Fatty Acidsp. 215
Inhibition of Cancer by Omega-3 Fatty Acidsp. 218
Conclusionp. 224
Referencesp. 224
18 Amino Acids and Related Compoundsp. 231
Amino Acidsp. 231
Garlicp. 236
Bromelain and Other Proteolytic Enzymesp. 239
Conclusionp. 243
Referencesp. 243
19 Flavonoidsp. 251
Introductionp. 251
Isoflavones, Flavones, and Flavonolsp. 252
Flavanols--EGCG and Related Green Tea Catechinsp. 260
Anthocyanidins and Proanthocyanidinsp. 263
Conclusionp. 266
Referencesp. 267
20 Nonflavonoid Phenolic Compoundsp. 275
CAPE and Propolisp. 275
Curcuminp. 278
Lignansp. 280
Stilbenes--Resveratrolp. 284
Quinonesp. 286
Conclusionp. 290
Referencesp. 291
21 Terpenesp. 297
Monoterpenesp. 297
Triterpenoidsp. 300
Saponinsp. 304
Sesquiterpenesp. 309
Conclusionp. 311
Referencesp. 311
22 Lipid-Soluble Vitaminsp. 317
Vitamin Ap. 317
Vitamin D[subscript 3]p. 322
Vitamin Ep. 326
Melatoninp. 330
Conclusionp. 333
Referencesp. 334
23 Natural Compounds, Chemotherapy, and Radiotherapyp. 343
Introductionp. 343
Effects of Natural Compounds on Chemotherapyp. 347
Effects of Natural Compounds on Radiotherapyp. 356
Drug Metabolismp. 358
Conclusionp. 359
Referencesp. 359
Appendix A Chemical Data on Natural Compoundsp. 369
Appendix B Pharmacokinetics, Pharmacodynamics, and Dose Scalingp. 377
Pharmacokinetic Modelsp. 377
Linking Pharmacodynamic and Pharmacokinetic Modelsp. 379
Scaling Between Speciesp. 381
Referencesp. 383
Appendix C Supplemental Material for Chapter 2p. 385
Appendix D Supplemental Material for Chapter 3p. 391
Appendix E Supplemental Material for Chapter 4p. 401
Appendix F Supplemental Material for Chapter 8p. 409
Appendix G Supplemental Material for Chapter 9p. 417
Appendix H Supplemental Material for Chapter 12p. 425
Appendix I Predictive Modelsp. 431
Free Oral Clearance (FOC) Modelp. 431
Total Oral Clearance (TOC) Modelp. 433
TOPKAT Modelp. 435
Oral-Intraperitoneal (ORIN) Modelp. 437
Referencesp. 442
Appendix J Dose Calculationsp. 445
Estimating Doses Based on Pharmacokinetic and In-vitro Datap. 445
Modifications to the Estimated Required Dosep. 447
LOAEL Dose Calculation Methodsp. 447
Dose-Dependent Bioavailabilityp. 448
Therapeutic and LOAEL Dose Estimates for Natural Compoundsp. 449
Referencesp. 484
Appendix K Supplemental Material for Chapter 19p. 493
Appendix L Software and Servicesp. 497
Appendix M Natural Compounds Research Fundp. 499
Acronymsp. 501
Indexp. 503